Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors - sprookjes - yvandenbroek - TriplyDB

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors

http://www.wikidata.org/entity/Q27684210

about

Modulation of Protein-Protein Interactions for the Development of Novel Therapeutics The bromodomain: from epigenome reader to druggable target Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors Targeting bromodomains: epigenetic readers of lysine acetylation Targeting BET bromodomains for cancer treatment BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.Drug Discovery Targeting Bromodomain-Containing Protein 4.Privileged diazepine compounds and their emergence as bromodomain inhibitors.Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.BET bromodomain inhibitors: a patent review.Biased multicomponent reactions to develop novel bromodomain inhibitors.Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity.Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4.Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands.Bromodomains and their pharmacological inhibitors.Selective Inhibition of CBX6: A Methyllysine Reader Protein in the Polycomb Family Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET Bromodomains Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014).Attach-Pull-Release Calculations of Ligand Binding and Conformational Changes on the First BRD4 Bromodomain.BET inhibitors in cancer therapeutics: a patent review.Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases.Identification of a Novel Class of BRD4 Inhibitors by Computational Screening and Binding Simulations.Combined experimental and theoretical studies of regio- and stereoselectivity in reactions of β-isoxazolyl- and β-imidazolyl enamines with nitrile oxides.Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors.In silico design and bioevaluation of selective benzotriazepine BRD4 inhibitors with potent antiosteoclastogenic activity.Direct access to isoxazolino and isoxazolo benzazepines from 2-((hydroxyimino)methyl)benzoic acid via a post-Ugi heteroannulation.A computational insight into binding modes of inhibitors XD29, XD35, and XD28 to bromodomain-containing protein 4 based on molecular dynamics simulations.Photoinduced reactions of both 2-formyl-2H-azirine and isoxazole: A theoretical study based on electronic structure calculations and nonadiabatic dynamics simulations.Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery

P2860

Q26775356-4C89EB51-E49D-47C6-BCE8-0B2DA392FA14 Q26999935-4F50A9C5-A787-42C6-9B45-319E64777CCF Q27701027-2CD521B2-5A48-4546-A4C8-369B43E83FF9 Q28238635-9A647AE2-4BEB-4FA1-94BB-3E7C8CD3B49C Q28263519-A336A8AE-6574-4028-8105-E96D60BDCBD8 Q30248629-A5F60407-A89C-4B1C-B60E-FF6E8BAE019C Q30352390-A166B27B-88A9-47D5-8B2A-0D07E93CD972 Q33671341-D4392A18-1074-4623-84D2-834BA8BA54D7 Q33725257-2BB7AC15-B690-420D-B704-696574B039D5 Q34263719-BEB55942-0CB3-4146-A8B1-88319E753D7D Q34386777-9CF5BB8F-1981-48AA-9EC9-F40746E8CD1D Q34525277-85268EC3-64E5-495E-B565-B171C7E3DF17 Q36206559-C61B3CB7-C8B0-4D50-96FF-D940673923B1 Q36310219-10FFAA35-66F4-4A7F-9313-60FDCA77849A Q38182138-C90E5AE2-0908-4A34-9BC7-B0E580DEF7E7 Q38185355-3A81A290-AE3F-40AF-B306-CD86080FA88C Q38434032-8EC81607-A42D-49B0-8CF5-01D2C301F7F2 Q38434073-D0998FD6-3545-4C82-806C-DA94B8EB3EC2 Q38547122-69710B43-2504-4E8A-AE30-88DE75E227E9 Q38753477-E9C5D1C1-ADF8-40C5-B008-2EE12674AF21 Q38753987-577064B0-FDB8-48DE-B783-9D8A4F224E99 Q38848379-B5BD413B-9575-4DF8-936A-772CBDA23EC0 Q41583442-ABBA6D62-9333-499F-8BE3-E57E351BCD68 Q42149159-D7ED4BFD-E8F1-464D-842D-3D2CA37C8BA3 Q47272627-A1DB54FF-8C11-4FA0-BBD2-1D9FCD81A632 Q48109630-F2711E56-8ED7-416F-9A42-13B63AABCCD1 Q48217289-59A7C881-0500-4382-9B80-707DFF746CB8 Q51023008-917B7504-AB19-4E23-8DC1-1E74D9C0B2E2 Q52933756-CEC85A9E-DB91-490F-99F5-EA061C29BF6F Q58697064-55D3DCB7-FADA-4BC3-B6F5-612FB9789F2E

P2860

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors

http://www.wikidata.org/entity/Q27684210

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors

@ast

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors

@en

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors

@nl

type

label

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors

@ast

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors

@en

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors

@nl

prefLabel

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors

@ast

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors

@en

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors

@nl

P1433

Q27684210-49F56866-AB31-4111-8CBC-A165B0F70320

P1476

Q27684210-A14936BF-5368-45A0-A5FF-D6F89D3DB935

P2093

Q27684210-06DE23B3-CDB4-4BDF-B1DA-4CFBD9B4A803

Q27684210-0E063229-AA81-4F3F-B58D-1AF692F583E6

Q27684210-0E40F900-826F-4E7E-872F-80F676706DCA

Q27684210-0F730E67-7490-40A6-883B-77CB639A7755

Q27684210-2D2A18A0-D886-4AED-9F19-F1C73C17E66B

Q27684210-2E80BF27-94D9-41CE-B386-0DACE9BB6A42

Q27684210-39F2DE68-6EC5-4293-999C-173B28378A4A

Q27684210-461EAEE6-5131-4219-A9A2-6ED1788FB4A3

Q27684210-4BAA3610-4587-4B4E-B52E-2FB0951B1C45

Q27684210-62E58B12-658E-4896-AD9B-95E910246F6B

P2860

Q27684210-09F0A5CA-EB8E-40CE-B7FB-26EAE34A2FC5

Q27684210-1AC77BEC-8E33-4744-8BA0-BD0D8269A745

Q27684210-21C2700E-AA63-4FFC-9E65-CA3222C16B93

Q27684210-239F7D24-DD32-4803-87DE-E93ABDD24DCE

Q27684210-35B7A4CD-F333-42AD-8AFE-96074DFD3321

Q27684210-3CC720D5-FD81-4D90-8D5E-A738CBB424AD

Q27684210-3E83E4BA-D23B-4105-AD00-749793F7B017

Q27684210-4E3DEF50-6D6B-4F08-9D62-277D7519EEFA

Q27684210-53C858E9-6C4D-46CA-AF9F-F6AB4531309A

Q27684210-682B913D-4C75-4541-B6D3-5237168209BC

P304

Q27684210-DCB15F66-A4DE-4A9A-8A33-DB652BB4A657

P31

Q27684210-986BBBD0-EDF1-449F-BD44-48AA249BC145

P356

Q27684210-6326D75F-A145-4D0B-93A3-25A2687497CD

P433

Q27684210-382D575E-C929-40E3-A267-F5C95B92A682

P478

Q27684210-C15B5604-F345-418E-ABE0-8530117C3327

P50

Q27684210-67042A54-F589-4437-AEE3-61DC286004A2

P577

Q27684210-440CA9B9-A20A-48B9-83A6-418074325C4B

P5875

Q27684210-9BB29B73-A9BB-4A71-993C-DE3C6D5553BC

P698

Q27684210-CC999CAC-E5CE-42D2-97A2-3713F53D4081

P921

Q27684210-1A79D3CC-46EA-4BC9-8E5C-40EA7ED0254E

Q27684210-99ECCC7F-F05A-4B5D-8555-F51086A7AAA0

P932

Q27684210-734672FB-375F-492F-AF9A-1D9A299672FA

P356

P1433

ACS Medicinal Chemistry Letters

P1476

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors

@en

P2093

Alexander M Taylor

http://www.w3.org/2001/XMLSchema#string

Alexandre Côté

http://www.w3.org/2001/XMLSchema#string

Barbara M Bryant

http://www.w3.org/2001/XMLSchema#string

Brian K Albrecht

http://www.w3.org/2001/XMLSchema#string

Christopher G Nasveschuk

http://www.w3.org/2001/XMLSchema#string

Eneida Pardo

http://www.w3.org/2001/XMLSchema#string

Florence Poy

http://www.w3.org/2001/XMLSchema#string

Hariharan Jayaram

http://www.w3.org/2001/XMLSchema#string

James E Audia

http://www.w3.org/2001/XMLSchema#string

Jennifer A Mertz

http://www.w3.org/2001/XMLSchema#string

P2860

Selective inhibition of BET bromodomains

Suppression of inflammation by a synthetic histone mimic

Discovery and characterization of small molecule inhibitors of the BET family bromodomains

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery

Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family

Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands

P304

835-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ML4001485

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Christophe Harmange

P577

2013-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262927146

http://www.w3.org/2001/XMLSchema#string

P698

24900758

http://www.w3.org/2001/XMLSchema#string

P921

Aagianik kimischri

P932

4027525

http://www.w3.org/2001/XMLSchema#string